Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis
- PMID:21263444
- PMCID: PMC3285768
- DOI: 10.1038/mp.2010.136
Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis
Abstract
A comprehensive literature search was performed to collate evidence of mitochondrial dysfunction in autism spectrum disorders (ASDs) with two primary objectives. First, features of mitochondrial dysfunction in the general population of children with ASD were identified. Second, characteristics of mitochondrial dysfunction in children with ASD and concomitant mitochondrial disease (MD) were compared with published literature of two general populations: ASD children without MD, and non-ASD children with MD. The prevalence of MD in the general population of ASD was 5.0% (95% confidence interval 3.2, 6.9%), much higher than found in the general population (≈ 0.01%). The prevalence of abnormal biomarker values of mitochondrial dysfunction was high in ASD, much higher than the prevalence of MD. Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls. Some markers correlated with ASD severity. Neuroimaging, in vitro and post-mortem brain studies were consistent with an elevated prevalence of mitochondrial dysfunction in ASD. Taken together, these findings suggest children with ASD have a spectrum of mitochondrial dysfunction of differing severity. Eighteen publications representing a total of 112 children with ASD and MD (ASD/MD) were identified. The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/MD compared with the general ASD population. The prevalence of many of these abnormalities was similar to the general population of children with MD, suggesting that ASD/MD represents a distinct subgroup of children with MD. Most ASD/MD cases (79%) were not associated with genetic abnormalities, raising the possibility of secondary mitochondrial dysfunction. Treatment studies for ASD/MD were limited, although improvements were noted in some studies with carnitine, co-enzyme Q10 and B-vitamins. Many studies suffered from limitations, including small sample sizes, referral or publication biases, and variability in protocols for selecting children for MD workup, collecting mitochondrial biomarkers and defining MD. Overall, this evidence supports the notion that mitochondrial dysfunction is associated with ASD. Additional studies are needed to further define the role of mitochondrial dysfunction in ASD.
Figures



Similar articles
- Unique acyl-carnitine profiles are potential biomarkers for acquired mitochondrial disease in autism spectrum disorder.Frye RE, Melnyk S, Macfabe DF.Frye RE, et al.Transl Psychiatry. 2013 Jan 22;3(1):e220. doi: 10.1038/tp.2012.143.Transl Psychiatry. 2013.PMID:23340503Free PMC article.
- Redox metabolism abnormalities in autistic children associated with mitochondrial disease.Frye RE, Delatorre R, Taylor H, Slattery J, Melnyk S, Chowdhury N, James SJ.Frye RE, et al.Transl Psychiatry. 2013 Jun 18;3(6):e273. doi: 10.1038/tp.2013.51.Transl Psychiatry. 2013.PMID:23778583Free PMC article.
- Biomarkers of mitochondrial dysfunction in autism spectrum disorder: A systematic review and meta-analysis.Frye RE, Rincon N, McCarty PJ, Brister D, Scheck AC, Rossignol DA.Frye RE, et al.Neurobiol Dis. 2024 Jul;197:106520. doi: 10.1016/j.nbd.2024.106520. Epub 2024 May 3.Neurobiol Dis. 2024.PMID:38703861
- A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures.Rossignol DA, Frye RE.Rossignol DA, et al.Mol Psychiatry. 2012 Apr;17(4):389-401. doi: 10.1038/mp.2011.165. Epub 2011 Dec 6.Mol Psychiatry. 2012.PMID:22143005Free PMC article.Review.
- Mitochondrial Dysfunction in Autism Spectrum Disorder: Unique Abnormalities and Targeted Treatments.Frye RE.Frye RE.Semin Pediatr Neurol. 2020 Oct;35:100829. doi: 10.1016/j.spen.2020.100829. Epub 2020 Jun 23.Semin Pediatr Neurol. 2020.PMID:32892956Review.
Cited by
- Analyzing the Potential Biological Determinants of Autism Spectrum Disorder: From Neuroinflammation to the Kynurenine Pathway.Savino R, Carotenuto M, Polito AN, Di Noia S, Albenzio M, Scarinci A, Ambrosi A, Sessa F, Tartaglia N, Messina G.Savino R, et al.Brain Sci. 2020 Sep 11;10(9):631. doi: 10.3390/brainsci10090631.Brain Sci. 2020.PMID:32932826Free PMC article.Review.
- Molecular and Therapeutic Aspects of Hyperbaric Oxygen Therapy in Neurological Conditions.Fischer I, Barak B.Fischer I, et al.Biomolecules. 2020 Aug 27;10(9):1247. doi: 10.3390/biom10091247.Biomolecules. 2020.PMID:32867291Free PMC article.Review.
- Integrated Systems Analysis Explores Dysfunctional Molecular Modules and Regulatory Factors in Children with Autism Spectrum Disorder.Gao H, Zhong J, Huang Q, Wu X, Mo X, Lu L, Liang H.Gao H, et al.J Mol Neurosci. 2021 Feb;71(2):358-368. doi: 10.1007/s12031-020-01658-w. Epub 2020 Jul 11.J Mol Neurosci. 2021.PMID:32653993
- Increased susceptibility to ethylmercury-induced mitochondrial dysfunction in a subset of autism lymphoblastoid cell lines.Rose S, Wynne R, Frye RE, Melnyk S, James SJ.Rose S, et al.J Toxicol. 2015;2015:573701. doi: 10.1155/2015/573701. Epub 2015 Jan 21.J Toxicol. 2015.PMID:25688267Free PMC article.
- Increased cerebral lactate levels in adults with autism spectrum disorders compared to non-autistic controls: a magnetic resonance spectroscopy study.Maier S, Nickel K, Lange T, Oeltzschner G, Dacko M, Endres D, Runge K, Schumann A, Domschke K, Rousos M, Tebartz van Elst L.Maier S, et al.Mol Autism. 2023 Nov 17;14(1):44. doi: 10.1186/s13229-023-00577-y.Mol Autism. 2023.PMID:37978557Free PMC article.
References
- APA Diagnostic and Statistical Manual of Mental Disorders4th edn.American Psychiatric Association: Washington, DC; 1994
- Rice C. Prevalence of autism spectrum disorders—Autism and Developmental Disabilities Monitoring Network, United States, 2006. MMWR Surveill Summ. 2009;58:1–20. - PubMed
- Gillberg C. Subgroups in autism: are there behavioural phenotypes typical of underlying medical conditions. J Intellect Disabil Res. 1992;36 (Part 3:201–214. - PubMed
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical